SPARC: An Orthogonal Cas12a/Cas13a Dual-Channel CRISPR Platform for Reliable SNV Identification and Mutation...

Area of Science:

• Molecular Biology
• Biotechnology
• Genetics

Background:

• CRISPR-based nucleic acid detection is crucial for diagnostics but faces challenges with signal ambiguity and specificity.
• Existing methods often struggle to differentiate true single nucleotide variants (SNVs) from absent targets, complicating interpretation.

Purpose of the Study:

• To introduce SPARC (specific and precise mutation recognition with Cas12a/Cas13a), an orthogonal dual-channel CRISPR assay for enhanced SNV detection reliability.
• To address limitations in current CRISPR platforms regarding specificity and signal interpretation for clinical diagnostics.

Main Methods:

• SPARC integrates AsCas12a for conserved region detection (internal reference) and DNA-activated LbuCas13a for high-specificity SNV detection.
• The assay utilizes recombinase polymerase amplification (RPA) and T7 exonuclease digestion.
• Orthogonal design distinguishes SNVs from target absence, improving diagnostic clarity.

Main Results:

• SPARC achieved ultra-high sensitivity, detecting nucleic acids at concentrations as low as 1 aM.
• The platform demonstrated robust clinical applicability by accurately detecting hepatitis B virus (HBV) and its YMDD resistance mutations.
• SPARC successfully differentiated between genuine SNVs and the absence of a target sequence.

Conclusions:

• SPARC offers an innovative and versatile CRISPR-based solution for reliable SNV detection.
• The platform significantly enhances diagnostic accuracy, with substantial potential for advancing clinical diagnostics and personalized medicine.
• SPARC overcomes common ambiguities in CRISPR-based detection, improving reliability for genetic mutation screening and pathogen identification.